<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870542</url>
  </required_header>
  <id_info>
    <org_study_id>S2019-0362-0001</org_study_id>
    <nct_id>NCT03870542</nct_id>
  </id_info>
  <brief_title>Multicenter, Prospective Study for Urinary Exosomal Biomarkers of Kidney Allograft Tubulointerstitial Fibrosis</brief_title>
  <acronym>UFO</acronym>
  <official_title>Multicenter, Prospective Observational Study to Identify and Validate a Composite of Urinary Exosomal Biomarkers for Kidney Allograft Tubulointerstitial Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to identify urinary exosomal biomarkers that represent the extent of
      graft fibrosis from deceased donor kidney transplantation. Urinary samples will be collected
      from deceased kidney donors at the time of procurement and zero-day kidney graft biopsy will
      be performed at the time of transplant. The association between urinary exosomes and the
      degree of graft fibrosis will be analyzed to identify biomarkers that represent fibrosis. The
      correlation between these biomarkers and graft long term outcomes will be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial fibrosis and tubular atrophy (IFTA), previously known as chronic allograft
      nephropathy (CAN), is diagnosed by pathologic changes involving all parts of the renal
      parenchyma and is one of the factors impacting graft survival and outcome. Currently, there
      is no standard to predict allograft fibrosis status at the time of procurement. Noninvasive
      biomarkers are necessary to monitor allograft status and to predict long-term outcomes.

      The investigators aim to conduct a multicenter prospective study to identify urinary exosomal
      biomarkers that represent the extent of graft fibrosis from deceased donor kidney
      transplantation. Urinary samples will be collected from deceased kidney donors at the time of
      procurement and zero-day kidney graft biopsy will be performed at the time of transplant. The
      zero-day biopsy tissue will be stained with Masson's Trichrome staining, Collagen I, III, IV
      immunostaining to evaluate the degree of fibrosis. Also, by ultracentrifuge, we will extract
      urinary exosomes and perform proteomics analysis and RNA-sequencing. The association between
      urinary exosomes and the degree of graft fibrosis will be analyzed to identify biomarkers
      that represent fibrosis. The correlation between these biomarkers and graft long term
      outcomes will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>kidney fibrosis</measure>
    <time_frame>zero-day (time of transplant)</time_frame>
    <description>the degree of kidney graft fibrosis on zero day biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney graft function</measure>
    <time_frame>6 months and 1 year post-transplant</time_frame>
    <description>Kidney graft function assessed with serum Creatinine, eGFR, CKD-EPI</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Renal Fibrosis</condition>
  <condition>Kidney Transplant Failure</condition>
  <arm_group>
    <arm_group_label>Deceased donor kidney transplantation</arm_group_label>
    <description>Patients receiving kidney transplants from deceased donor in the participating centers during the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>kidney transplantation</intervention_name>
    <description>Kidney transplant for end-stage renal disease from deceased kidney donors</description>
    <arm_group_label>Deceased donor kidney transplantation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine samples from deceased kidney donors, zero-day kidney graft biopsy specimen, Urine and
      blood samples of kidney transplant recipients during a follow up of one year
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        end-stage renal disease patients receiving kidney transplantation from deceased donors who
        have the ability to provide content for this study, patients willing to provide content and
        participate in this study during the follow-up period
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end-stage renal disease patients receiving kidney transplantation from deceased donors
             who have the ability to provide content for this study

        Exclusion Criteria:

          -  multi-organ transplantation candidate or history of previous transplant, history of
             extra-renal solid organ or bone marrow or stem cell transplant, active infection,
             history of recent intoxication of alcohol or substance abuse within 24 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Shin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Shin, MD, PhD</last_name>
    <phone>82-2-3010-3964</phone>
    <email>sshin@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUNG SHIN, Dr.</last_name>
      <email>sshin@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Singh T, Astor B, Zhong W, Mandelbrot D, Djamali A, Panzer S. Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides. Transplant Direct. 2017 Oct 18;3(11):e223. doi: 10.1097/TXD.0000000000000736. eCollection 2017 Nov.</citation>
    <PMID>29184911</PMID>
  </reference>
  <reference>
    <citation>Hanssen O, Erpicum P, Lovinfosse P, Meunier P, Weekers L, Tshibanda L, Krzesinski JM, Hustinx R, Jouret F. Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients. Part I. In vivo imaging methods. Clin Kidney J. 2017 Feb;10(1):97-105. doi: 10.1093/ckj/sfw062. Epub 2016 Jul 28. Review.</citation>
    <PMID>28643821</PMID>
  </reference>
  <reference>
    <citation>Gámez-Valero A, Lozano-Ramos SI, Bancu I, Lauzurica-Valdemoros R, Borràs FE. Urinary extracellular vesicles as source of biomarkers in kidney diseases. Front Immunol. 2015 Jan 30;6:6. doi: 10.3389/fimmu.2015.00006. eCollection 2015. Review.</citation>
    <PMID>25688242</PMID>
  </reference>
  <reference>
    <citation>Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B, Serur D, Mouradian J, Schwartz JE, Suthanthiran M. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001 Mar 29;344(13):947-54.</citation>
    <PMID>11274620</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Nolasco B, Wang M, Prunevieille A, Benichou G. Emerging role of exosomes in allorecognition and allograft rejection. Curr Opin Organ Transplant. 2018 Feb;23(1):22-27. doi: 10.1097/MOT.0000000000000489. Review.</citation>
    <PMID>29189413</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>March 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

